Education
About Us
Working with TipRanks
Follow Us
Mannkind Corp. (MNKD)
NASDAQ:MNKD
Earnings Data
Report Date
May 07, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
0.04Last Year’s EPS
0.04Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 26, 2025
|% Change Since: -7.50%
|Next Earnings Date:May 07, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance and growth in key areas such as Tyvaso DPI and Afrezza revenues, alongside a significant reduction in debt. However, there are challenges in the pipeline development and preparation for the pediatric launch of Afrezza, as well as a slight decline in V-Go revenues. Overall, the positive financial results and strategic initiatives outweigh the challenges faced.Company Guidance
During the MannKind Corporation's Fourth Quarter and Year-End 2024 Financial Results Earnings Call, CEO Michael Castagna highlighted several metrics indicating the company's strong performance and strategic direction. The endocrine business unit reported Q4 revenue of $23 million and full-year revenue of $82 million. Overall, MannKind achieved $77 million in Q4 revenue, with total 2024 revenues reaching $286 million, a 43% increase from the previous year. The company also ended the year with a cash position of $203 million and reduced its debt principal by $236 million. The Afrezza program saw a 17% year-over-year revenue increase, contributing $64 million for the year. Tyvaso DPI royalties added $27 million in Q4, totaling $102 million for the year, which helped fund pipeline developments. Additionally, MannKind is advancing its clofazamine inhalation suspension program with 70% of Phase III sites activated and aims for an interim readout in 2026. Looking forward, MannKind is preparing for a pediatric indication filing for Afrezza in the first half of 2025, with potential approval in 2026, and anticipates that achieving a 10% market share in pediatrics could generate approximately $150 million in revenue.Record Revenue in Endocrine Business Unit
Q4 revenue reached $23 million, with full-year revenue at $82 million. This was a record for the endocrine business unit.
Successful Tyvaso DPI Collaboration
Tyvaso DPI-related revenues exceeded $200 million in 2024, marking the first billion-dollar product for United Therapeutics and showcasing the success of the Technosphere platform.
Significant Revenue Growth
Fourth quarter revenues were $77 million, showing a 31% increase over the previous year's fourth quarter. Full year 2024 revenue was $286 million, a 43% increase over the prior year.
Reduction in Debt
Reduced debt principal by $236 million in 2024, leaving a minimal debt balance of $36 million related to senior convertible notes.
Afrezza Revenue Growth
Afrezza net revenue for the fourth quarter was $18 million, an 18% increase, and full-year revenue was $64 million, a 17% increase over 2023.
---
MNKD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
MNKD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 26, 2025 | $5.47 | $5.23 | -4.39% |
| Nov 07, 2024 | $7.39 | $7.34 | -0.68% |
| Aug 07, 2024 | $5.27 | $5.01 | -4.93% |
| May 08, 2024 | $4.40 | $4.31 | -2.05% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Mannkind Corp. (MNKD) report earnings?
Mannkind Corp. (MNKD) is schdueled to report earning on May 07, 2025, TBA Not Confirmed.
What is Mannkind Corp. (MNKD) earnings time?
Mannkind Corp. (MNKD) earnings time is at May 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MNKD EPS forecast?
MNKD EPS forecast for the fiscal quarter 2025 (Q1) is 0.04.
---